XALATAN (latanoprost), glaucoma eye drops

OPHTHALMOLOGY - New indication

Opinions on drugs - Posted on Jun 09 2016

Extension of Inclusion

XALATAN now has marketing authorisation in reduction of elevated intraocular pressure in paediatric patients with elevated intraocular pressure (IOP) and paediatric glaucoma.
A randomised clinical study demonstrated its non-inferiority relative to timolol on mean reduction of intraocular pressure IOP after 12 weeks of treatment.
XALATAN contains benzalkonium chloride in its formulation and no long-term safety data are available.
XALATAN, like other eye drops, can be useful short-term, while awaiting surgery, or as an additional treatment with surgery whose result is insufficient, as well as long-term in other less aggressive forms of paediatric glaucoma.

Substantial

no clinical added value

Therapeutic use

Évaluation des médicaments

All our publications

My account